Scientific Publications Citizens of Science

In our quest to invent life-transforming medicines for people with serious diseases, we encourage our colleagues to publish their research in leading scientific journals.

The links on this page are not affiliated with Regeneron Pharmaceuticals, Inc. Links to sites outside of Regeneron are provided as a resource to the viewer. Regeneron accepts no responsibility for the content of linked sites.

Featured Publications
Genetics
Genetic risk factors for COVID-19 and influenza are largely distinct

Published in Nat Genet. 2024 Aug 5. doi: 10.1038/s41588-024-01844-1. Online ahead of print.

A deep catalogue of protein-coding variation in 983,578 individuals

Published in Nature. 2024 May 20. doi: 10.1038/s41586-024-07556-0. Epub ahead of print.

Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone

Published in Nature. 2024 Sep 11. doi: 10.1038/s41586-024-07903-1. Online ahead of print.

Hematology
Peripheral human red blood cell development in human immune system mouse model with heme oxygenase-1 deficiency

Published in Blood Adv. 2024 Sep 30:bloodadvances.2023011754. doi: 10.1182/bloodadvances.2023011754. Online ahead of print.

Immunology & Inflammation
Designing meaningful continuous representations of T cell receptor sequences with deep generative models

Published in Nat Commun. 2024 May 20;15(1):4271. doi: 10.1038/s41467-024-48198-0.

Infectious Diseases
Population Pharmacokinetics of Casirivimab and Imdevimab in Pediatric and Adult Non-Infected Individuals, Pediatric and Adult Ambulatory or Hospitalized Patients or Household Contacts of Patients Infected with SARS-COV-2

Published in Pharm Res. 2024 Sep 18. doi: 10.1007/s11095-024-03764-5. Online ahead of print.

Oncology
LTβR Agonism Promotes Anti-Tumor Immune Responses via Modulation of the Tumor Microenvironment

Published in Cancer Res. 2024 Aug 13. doi: 10.1158/0008-5472.CAN-23-2716. Online ahead of print.

Technology
Distinct chemical degradation pathways of AAV1 and AAV8 under thermal stress conditions revealed by analytical anion exchange chromatography and LC-MS-based peptide mapping

Published in J Pharm Biomed Anal. 2024 Aug 26;251:116452. doi: 10.1016/j.jpba.2024.116452. Online ahead of print.

Immunology & Inflammation
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

Published in N Engl J Med. 2024 May 20. doi: 10.1056/NEJMoa2401304.

Dupilumab Efficacy in Children With Type 2 Asthma Receiving High/Medium-Dose ICS (VOYAGE)

Published in J Allergy Clin Immunol Pract. 2024 Aug 27:S2213-2198(24)00858-4. doi: 10.1016/j.jaip.2024.08.038. Online ahead of print.

Infectious Diseases
Patient-Reported Outcomes in COVID-19 Treatment with Monoclonal Antibodies Reveal Benefits in Return to Usual Activities

Published in Infect Dis Ther. 2024 Jul 3. doi: 10.1007/s40121-024-01013-1. Online ahead of print.

Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial

Published in Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00421-3. doi: 10.1016/S1473-3099(24)00421-3. Online ahead of print.

Obesity, Muscle & Metabolism
Characterization of flare-ups and impact of Garetosmab in adults with Fibrodysplasia Ossificans Progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial

Published in J Bone Miner Res. 2024 Aug 31:zjae140. doi: 10.1093/jbmr/zjae140. Online ahead of print.

Oncology
Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial

Published in Future Oncol. 2024 Jul 29:1-10. doi: 10.1080/14796694.2024.2358670. Online ahead of print.

Rare Diseases
Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments

Published in Orphanet J Rare Dis. 2024 Aug 8;19(1):290. doi: 10.1186/s13023-024-03277-9.

Back
to top